Because of their implications in several pathological conditions, α4β2* nicotinic acetylcholine receptors (nAChRs) are potential targets for the treatment of nicotine dependence, pain, and many psychiatric and neurodegenerative diseases. However, they exist in various subtypes, and finding selective tools to investigate them has proved challenging. The nicotinic receptor agonist, 5-iodo-A-85380 (5IA), has helped in delineating the function of β2-containing subtypes in vitro; however, much is still unknown about its behavioral effects. Furthermore, its effectiveness on α6-containing subtypes is limited.
Aims:
To investigate the effects of 5IA on nociception (formalin, hot-plate, and tail-flick tests), locomotion, hypothermia, and conditioned reward after acute and repeated administration, and to examine the potential role of β2 and α6 nAChR subunits in these effects. Lastly, its selectivity for expressed low sensitivity (LS) and high sensitivity (HS) α4β2 receptors is investigated.
Results:
5IA dose-dependently induced hypothermia, locomotion suppression, conditioned place preference, and antinociception (only in the formalin test but not in the hot-plate or tail-flick tests). Furthermore, these effects were mediated by β2 but not α6 nicotinic subunits. Finally, we show that 5-iodo-A-85380 potently activates both stoichiometries of α4β2 nAChRs with differential efficacies, being a full agonist on HS α4(2)β2(3) nAChRs, and a partial agonist on LS α4(3)β2(2) nAChRs and α6-containing subtypes as well.
AickinMGenslerH (1996) Adjusting for multiple testing when reporting research results: The Bonferroni vs Holm methods. Am J Public Health86: 726–728. DOI: 10.2105/AJPH.86.5.726.
2.
AkinolaLSMckiverBTomaW, et al. (2019). C57BL/6 substrain differences in pharmacological effects after acute and repeated nicotine administration. Brain Sci9(10): 244. DOI: 10.3390/brainsci9100244.
3.
AlkondonMAlbuquerqueEX (2004) The nicotinic acetylcholine receptor subtypes and their function in the hippocampus and cerebral cortex. Prog Brain Res145: 109–120. DOI: 10.1016/S0079-6123(03)45007-3.
4.
AndersonSMBrunzellDH (2015) Anxiolytic-like and anxiogenic-like effects of nicotine are regulated via diverse action at β2*nicotinic acetylcholine receptors. Br J Pharmacol172: 2864–2877. DOI: 10.1111/bph.13090.
5.
AtwellLJacobsonA (1978) The search for less harmful analgesics. Lab Anim7: 42–47.
6.
BovetDBovet-NittiFOliverioA (1967) Action of nicotine on spontaneous and acquired behavior in rats and mice. Ann N Y Acad Sci142: 261–267. DOI: 10.1111/J.1749-6632.1967.TB13728.X.
7.
BrunoriGSchochJMercatelliD, et al. (2018) Influence of neuropathic pain on nicotinic acetylcholine receptor plasticity and behavioral responses to nicotine in rats. Pain159: 2179–2191. DOI: 10.1097/J.PAIN.0000000000001318.
8.
CaldaroneBJWangDPatersonNE, et al. (2011) Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380. Psychopharmacol217: 199–210. DOI: 10.1007/S00213-011-2271-Y.
9.
ClarkePBSKumarR (1983) The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. Br J Pharmacol78: 329–337. DOI: 10.1111/J.1476-5381.1983.TB09398.X.
10.
CurzonPNikkelALBannonAW, et al. (1998) Differences between the antinociceptive effects of the cholinergic channel activators A-85380 and (+/-)-epibatidine in rats. J Pharmacol Exp Ther287: 847–853.
11.
D’amourFESmithDL (1941) A method for determining loss of pain sensation. J Pharmacol Exp Ther72: 74–79.
12.
DeweyWLHarrisLSHowesJF, et al. (1970) The effect of various neurohumoral modulators on the activity of morphine and the narcotic antagonists in the tail-flick and phenylquinone tests. J Pharmacol Exp Ther175: 435–442.
EddyNBLeimbachD (1953) Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther107: 385–393.
15.
FasoliFMorettiMZoliM, et al. (2016) In vivo chronic nicotine exposure differentially and reversibly affects upregulation and stoichiometry of α4β2 nicotinic receptors in cortex and thalamus. Neuropharmacol108: 324–331. DOI: 10.1016/J.NEUROPHARM.2016.04.048.
16.
FloresCMRogersSWPabrezaLA, et al. (1992) A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol41: 31–37.
17.
FowlerCDArendsMAKennyPJ (2008) Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice. Behav Pharmacol19: 461–484. DOI: 10.1097/FBP.0b013e32830c360e.
18.
FreitasKCarrollFINegusSS (2016) Comparison of effects produced by nicotine and the α4β2-selective agonist 5-I-A-85380 on intracranial self-stimulation in rats. Exp Clin Psychopharmacol24: 65–75. DOI: 10.1037/pha0000055.
19.
GottiCClementiFFornariA, et al. (2009) Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol78: 703–711. DOI: 10.1016/j.bcp.2009.05.024.
20.
GrabusSDMartinBRBrownSE, et al. (2006) Nicotine place preference in the mouse: Influences of prior handling, dose and strain and attenuation by nicotinic receptor antagonists. Psychopharmacol184: 456–463. DOI: 10.1007/s00213-006-0305-7.
21.
GradySRSalminenOMcIntoshJM, et al. (2010) Mouse striatal dopamine nerve terminals express alpha4alpha5beta2 and two stoichiometric forms of alpha4beta2*-nicotinic acetylcholine receptors. J Mol Neurosci40: 91–95. DOI: 10.1007/S12031-009-9263-Y.
22.
HamoudaAKBautistaMRAkinolaLS, et al. (2021) Potentiation of (α4)2(β2)3, but not (α4)3(β2)2, nicotinic acetylcholine receptors reduces nicotine self-administration and withdrawal symptoms. Neuropharmacol : 108568. DOI: 10.1016/j.neuropharm.2021.108568.
HolladayMWDartMJLynchJK (1997) Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med Chem40: 4169–4194. DOI: 10.1021/jm970377o.
ImprogoMRDScofieldMDTapperAR, et al. (2010) The nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: dual role in nicotine addiction and lung cancer. Prog Neurobiol92: 212–226. DOI: 10.1016/j.pneurobio.2010.05.003.
27.
JareczekFJWhiteSRHammondDL (2017) Plasticity in brainstem mechanisms of pain modulation by nicotinic acetylcholine receptors in the rat. ENeuro4: ENEURO.0364–16.2017. DOI: 10.1523/eneuro.0364-16.2017.
28.
JonesSSudweeksSYakelJL (1999) Nicotinic receptors in the brain: Correlating physiology with function. Trends Neurosci22: 555–561. DOI: 10.1016/s0166-2236(99)01471-x.
29.
KorenAOHortiAGMukhinAG, et al. (1998) 2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: Synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. J Med Chem41: 3690–3698. DOI: 10.1021/jm980170a.
30.
KotaDMartinBRRobinsonSE, et al. (2007) Nicotine dependence and reward differ between adolescent and adult male mice. J Pharmacol Exp Ther322: 399–407. DOI: 10.1124/jpet.107.121616.
31.
KulakJMSumJMusachioJL, et al. (2002) 5-Iodo-A-85380 binds to alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors (nachrs) as well as alpha4beta2* subtypes. J Neurochem81: 403–406. DOI: 10.1046/j.1471-4159.2002.00868.x.
32.
KumarVKimKJosephC, et al. (2013) C57BL/6N mutation in cytoplasmic FMRP interacting protein 2 regulates cocaine response. Science342: 1508–1512. DOI: 10.1126/science.1245503.
33.
KuryatovALindstromJ (2011) Expression of functional human α6β2β3* acetylcholine receptors in Xenopus laevis oocytes achieved through subunit chimeras and concatamers. Mol Pharmacol79: 126–140. DOI: 10.1124/mol.110.066159.
34.
KuryatovAOnksenJLindstromJ (2008) Roles of accessory subunits in alpha4beta2(*) nicotinic receptors. Mol Pharmacol74: 132–143. DOI: 10.1124/MOL.108.046789.
LiuXKorenAOYeeSK, et al. (2003) Self-administration of 5-iodo-A-85380, a beta2-selective nicotinic receptor ligand, by operantly trained rats. Neuroreport, 14: 1503–1505. DOI: 10.1097/00001756-200308060-00020.
37.
LuceroLMWeltzinMMEatonJB, et al. (2016) Differential α4(+)/(−)β2 agonist-binding site contributions to α4β2 nicotinic acetylcholine receptor function within and between isoforms. J Biol Chem291: 2444–2459. DOI: 10.1074/JBC.M115.684373.
38.
MamedeMIshizuKUedaM, et al. (2004). Quantification of human nicotinic acetylcholine receptors with 123 I-5IA SPECT. J Nucl Med45: 1458–1470.
39.
McEvoyJPAllenTB (2002) The importance of nicotinic acetylcholine receptors in schizophrenia, bipolar disorder and Tourette’s syndrome. Curr Drug Targets CNS Neurol Disord1: 433–442. DOI: 10.2174/1568007023339210.
40.
MoroniMZwartRSherE, et al. (2006) Α4β2 nicotinic receptors with high and low acetylcholine sensitivity: Pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine. Mol Pharmacol70: 755–768. DOI: 10.1124/mol.106.023044.
41.
MukhinAGGündischDHortiAG, et al. (2000) 5-Iodo-A-85380, an α4β2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol57: 642–649. DOI: 10.1124/mol.57.3.642.
42.
MusachioJLScheffelUFinleyPA, et al. (1998) 5-[I-125/123]lodo-3 (2 (S)-azetidinylmethoxy) pyridine, a radioiodinated analog of A-85380 for in vivo studies of central nicotinic acetylcholine receptors. Life Sci62: 351–357.
43.
NashmiRXiaoCDeshpandeP, et al. (2007) Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: Basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path. J Neurosci27: 8202–8218. DOI: 10.1523/Jneurosci.2199-07.2007.
44.
NelsonMEKuryatovAChoiCH, et al. (2003) Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors. Mol Pharmacol63: 332–341. DOI: 10.1124/mol.63.2.332.
NybäckHHalldinCÅhlinA, et al. (1994) PET studies of the uptake of (S)- and (R)-[11C]nicotine in the human brain: Difficulties in visualizing specific receptor binding in vivo. Psychopharmacol115: 31–36. DOI: 10.1007/BF02244748.
47.
OgawaMTsukadaHHatanoK, et al. (2009) Central in vivo nicotinic acetylcholine receptor imaging agents for positron emission tomography (PET) and single photon emission computed tomography (SPECT). Bio Pharm Bull32: 337–340. DOI: 10.1248/bpb.32.337.
48.
OkadaHOuchiYOgawaM, et al. (2013) Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer’s aetiopathology. Brain136: 3004–3017. DOI: 10.1093/BRAIN/AWT195.
49.
PapkeRL (1993) The kinetic properties of neuronal nicotinic receptors: Genetic basis of functional diversity. Prog Neurobiol41: 509–531. DOI: 10.1016/0301-0082(93)90028-q.
50.
PapkeRLBrunzellDHDe BiasiM (2020) Cholinergic receptors and addiction. Curr Top Behav Neurosci45: 123–151. DOI: 10.1007/7854_2020_139.
51.
PapkeRLPorter PapkeJK (2002) Comparative pharmacology of rat and human alpha7 nachr conducted with net charge analysis. Br J Pharmacol137: 49–61. DOI: 10.1038/sj.bjp.0704833.
52.
PapkeRLStokesC (2010) Working with opusxpress: Methods for high volume oocyte experiments. Methods51: 121–133. DOI: 10.1016/j.ymeth.2010.01.012.
53.
PapkeRLStokesCMuldoonP, et al. (2013) Similar activity of mecamylamine stereoisomers in vitro and in vivo. Eur J Pharmacol720: 264–275. DOI: 10.1016/j.ejphar.2013.10.018.
54.
PimlottSLPiggottMOwensJ, et al. (2004) Nicotinic acetylcholine receptor distribution in Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, and vascular dementia: In vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology29: 108–116. DOI: 10.1038/sj.npp.1300302.
55.
PismataroMCHorensteinNAStokesC, et al. (2020) Design, synthesis, and electrophysiological evaluation of NS6740 derivatives: Exploration of the structure-activity relationship for alpha7 nicotinic acetylcholine receptor silent activation. Eur J Med Chem205: 112669. DOI: 10.1016/j.ejmech.2020.112669.
56.
QuikMWonnacottS (2011) α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson’s disease. Pharmacol Rev63: 938. DOI: 10.1124/PR.110.003269.
57.
RueterLEDonnelly-RobertsDLCurzonP, et al. (2006) A-85380: a pharmacological probe for the preclinical and clinical investigation of the alphabeta neuronal nicotinic acetylcholine receptor. CNS Drug Rev12: 100–112. DOI: 10.1111/j.1527-3458.2006.00100.x.
58.
RueterLEKohlhaasKLCurzonP, et al. (2003) Peripheral and central sites of action for A-85380 in the spinal nerve ligation model of neuropathic pain. Pain103: 269–276. DOI: 10.1016/S0304-3959(02)00455-4.
59.
SrinivasanRPantojaRMossFJ, et al. (2011) Nicotine up-regulates alpha4beta2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning. J Gen Physiol137: 59–79. DOI: 10.1085/JGP.201010532.
60.
StolermanIPBunkerPGarvikME (1974) Nicotine tolerance in rats; role of dose and dose interval. Psychopharmacologia34: 317–324.
61.
StolermanIPJarvikME (1973) Acute and chronic tolerance to nicotine measured by activity in rats. Psychopharmacologia30: 329–342.
62.
UedaMIidaYTominagaA, et al. (2010) Nicotinic acetylcholine receptors expressed in the ventralposterolateral thalamic nucleus play an important role in anti-allodynic effects. Br J Pharmacol159: 1201–1210. DOI: 10.1111/j.1476-5381.2009.00613.x.
63.
UedaMIidaYTominagaA, et al. (2011) In vivo relationship between thalamic nicotinic acetylcholine receptor occupancy rates and antiallodynic effects in a rat model of neuropathic pain: Persistent agonist binding inhibits the expression of antiallodynic effects. Synapse65: 77–83. DOI: 10.1002/syn.20819.
64.
UmezuTLaneHYReidLD (2012) Unusual effects of nicotine as a psychostimulant on ambulatory activity in mice. ISRN Pharmacol2012: 170981. DOI: 10.5402/2012/170981.
65.
VaupelDBMukhinAGKimesAS, et al. (1998) In vivo studies with [125I]5-I-A-85380, a nicotinic acetylcholine receptor radioligand. Neuroreport9: 2311–2317. DOI: 10.1097/00001756-199807130-00030.
66.
VinclerMEisenachJC (2004) Plasticity of spinal nicotinic acetylcholine receptors following spinal nerve ligation. Neurosci Res48: 139–145. DOI: 10.1016/j.neures.2003.10.007.
67.
ZhangJXiaoYDe JordanKG, et al. (2012) Analgesic effects mediated by neuronal nicotinic acetylcholine receptor agonists: Correlation with desensitization of α4β2* receptors. Eur J Pharm Sci47: 813–823. DOI: 10.1016/J.EJPS.2012.09.014.
68.
ZhouYNelsonMEKuryatovA, et al. (2003) Human alpha4beta2 acetylcholine receptors formed from linked subunits. J Neurosci23: 9004–9015. DOI: 10.1523/jneurosci.23-27-09004.2003.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
